US experts endorse Moderna's first mRNA flu vaccine, paving the way for a new mRNA seasonal shot
Executive summary: A US expert panel issued a positive evaluation of Moderna's mRNA flu vaccine, recommending its approval for the upcoming season. If approved, it would be the first mRNA‑based flu vaccine, expanding Moderna's product portfolio and confirming the viability of mRNA technology for seasonal infectious diseases.
Who is involved: Moderna, the US expert panel, the US Food and Drug Administration, patients and healthcare providers
Likely next: The FDA will review the submission, with a decision expected later in 2026; competitors may accelerate their own mRNA flu programs in response.
A US expert panel issued a positive evaluation of Moderna's mRNA flu vaccine, recommending its approval for the upcoming season. The report highlights the potential of mRNA technology to be used beyond COVID‑19 vaccines. No competing expert opinions were cited in the provided sources. The decision will be closely watched by regulators, competitors and investors.
Analysis — what this means
Likely next events
- FDA review and possible approval decision in 2026
- Market launch planning by Moderna for the upcoming flu season
- Competitor response with own mRNA flu initiatives
Sectors affected
- Healthcare
- Pharmaceuticals
- Biotechnology
Regulatory implications
- Establishes a regulatory pathway for mRNA seasonal vaccines
- May influence future FDA guidance on novel platform approvals
Historical parallels
- COVID‑19 mRNA vaccine rollout
- First FDA‑approved mRNA therapy for cancer (Moderna's mRNA‑4157)
- Early 2000s RNA interference approaches that promised platform versatility
Key entities
Open the full interactive case file on Beyond →